Adjuvant Efficacy of mOMV against Avian Influenza Virus Infection in Mice

• Published in: The journal of microbiology 2013, 51(5), , pp.682-688
• Main Authors: Lee, B.J., Chungbuk National University, Cheongju, Republic of Korea, Lee, S.H., Korea Research Institute of Bioscience and Biotechnology (KRIBB), Chungbuk, Republic of Korea, Song, M.S., Chungbuk National University, Cheongju, Republic of Korea, Pascua, P.N.Q., Chungbuk National University, Cheongju, Republic of Korea, Kwon, H.I., Chungbuk National University, Cheongju, Republic of Korea, Park, S.J., Chungbuk National University, Cheongju, Republic of Korea, Kim, E.H., Chungbuk National University, Cheongju, Republic of Korea, Decano, A., Chungbuk National University, Cheongju, Republic of Korea, Kim, S.M., Chungbuk National University, Cheongju, Republic of Korea, Lim, G.J., Chungbuk National University, Cheongju, Republic of Korea, Kim, D.J., Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea, Chang, K.T., Korea Research Institute of Bioscience and Biotechnology (KRIBB), Chungbuk, Republic of Korea, Kim, S.H., Korea Research Institute of Bioscience and Biotechnology (KRIBB), Chungbuk, Republic of Korea, Choi, Y.K., Chungbuk National University, Cheongju, Republic of Korea
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - administration & dosage; Alum; Aluminum; aluminum hydroxide; Aluminum Hydroxide - administration & dosage; Animals; antibodies; Antibodies, Viral - blood; Antigens; Avian flu; avian influenza; Avian influenza virus; AVIAN INFLUENZAVIRUS; Biomedical and Life Sciences; Body weight; body weight changes; Cell-Derived Microparticles; Cross Reactions; death; Disease Models, Animal; Genetics; H5N2 vaccine,mOMV adjuvant; humans; immunity; Infections; Influenza A virus; Influenza A Virus, H5N2 Subtype - genetics; Influenza A Virus, H5N2 Subtype - immunology; Influenza Vaccines - administration & dosage; Influenza Vaccines - genetics; Influenza Vaccines - immunology; INFLUENZAVIRUS AVIAIRE; Life Sciences; Mice; Microbiology; Orthomyxoviridae Infections - immunology; Orthomyxoviridae Infections - prevention & control; Pandemics; Research centers; Reverse Genetics; Survival; Survival Analysis; survival rate; vaccination; Vaccination - methods; vaccine adjuvants; Vaccines; viral antigens; Viral infections; Virology; VIRUS DE LA INFLUENZA AVIAR; virus transmission; Viruses; 생물학
• ISSN: 1225-8873; 1976-3794
• DOI: 10.1007/s12275-013-3411-3

Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 103.5 EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.